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Since the re-introduction of clozapine in 1988, the so-
called atypical or second generation antipsychotics
(SGAs) have contributed considerably to the treatment of
schizophrenia. The term "atypical" was at first given to
clozapine because of its low propensity to cause extrapy-
ramidal symptoms. This term has been applied uncriti-
cally to a series of drugs despite their striking differences
in chemistry, pharmacology and specific clinical action
profile. Their use also may be limited because of various
existing controversies. At first, there is the question
whether SGAs have to be preferred over the older, conven-
tional first generation antipsychotics (FGAs). Secondly,
there has been an ongoing debate to differentiate between
them in terms of efficacy and safety.
The initial enthusiasm that most of the second generation
antipsychotics (SGAs) showed a better efficacy and tolera-
bility profile over the FGAs was subsided over the publica-
tion of a series of meta-analyses, the most recent being the
first results of the CATIE study. These showed that there
was no clear evidence of the advantage of SGAs compared
to the FGAs. Treatment guidelines from various institu-
tions issued analogous and equivocating recommenda-
tions between the two antipsychotic groups. Therefore,
the clinician has remained free to make his own choice.
There have been many publications comparing SGAs with
FGAs, in the regulatory process of the drugs. For example,
a meta-analysis comparing SGAs over FGAs found
reduced dropout and treatment failure rates with risperi-
done in comparison with haloperidol. Other efficacy trials
have tried to find differences in efficacy between the SGAs
but with conflicting results. In one study, clozapine
proved more effective than risperidone in treatment resist-
ant schizophrenia but methodological flaws prompt for
cautiouness for the interpretation of the results A big issue
was raised with two studies comparing the efficacy of ris-
peridone versus olanzapine. The first showed an advan-
tage of olanzapine over risperidone and the second
showed the opposite. Two studies comparing ziprasidone
with olanzapine and ziprasidone with risperidone didn't
disclose any advantage in efficacy of either agent over the
other. A better tolerability profile was found with ziprasi-
done. Studies involving quetiapine showed that this agent
had similar efficacy to risperidone and olanzapine. Switch
studies showed that the use of aripiprazole maintained
the clinical effect acquired by the previous agent. in
another study, aripiprazole showed similar efficacy with
risperidone. Amisulpride, an atypical antipsychotic with a
different mechanism of action than the other SGAs, is an
effective agent for the treatment of acute exacerbations as
well as for the chronic treatment of positive and especially
negative symptoms of schizophrenia. Compared with
haloperidol in two studies, showed at least the same rate
of improvement in positive symptoms and a clear advan-
tage in long term over haloperidol in negative, suggested
no efficacy differences between them, when the haloperi-
dol equivalent didn't exceed 12 mg/day. In the light of
most recent evidence comparing the relative efficacy of the
SGAs, there are no clear-cut differences between them. It
is up to the clinician to weigh the risks, the benefits and
the cost of each drug and choose the most appropriate
therapy for the individual patient.
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